Author Archives: admin


Stem Cell Clinic > Articles by: admin

Regeneron, Trump, and the alleged hypocrisy of the pro-life movement – Christian Post

By Stem Cell Doctors

By Michael Brown, CP Op-Ed Contributor | Thursday, October 15, 2020

Have you heard the latest? Trump cannot be pro-life since he used and is promoting the anti-COVID drug Regeneron, which was allegedly developed with the help of fetal tissue. And pro-life organizations are being hypocritical by refusing to condemn the drug. Is there any truth to these charges?

As reported by the UK Metro, Trump faces hypocrisy allegations after it was revealed Regeneron is made from stem cells originally taken from an embryonic kidney. That kidney was taken during an elective abortion performed in the Netherlands during the 1970s.

More bluntly, the MIT Technology Review claimed, Trumps antibody treatment was tested using cells originally derived from an abortion.

The Trump administration has looked to curtail research with fetal cells. But when it was life or death for the president, no one objected.

As for pro-life organizations, a lengthy headline on Business Insider stated, Antiabortion groups say they stand behind Trump's use of a drug tested on cells derived from an aborted fetus because the president was not involved with that abortion.

How should pro-life Trump voters respond to these concerns?

Lets say that Regeneron was actually developed with the help of fetal tissue. Does anyone actually think that doctors came to Trump and said, Mr. President, we have an experimental drug that was tested and developed using tissue from an aborted baby from the 1970s. How do you feel about using this?

Only the most hardened anti-Trumper could imagine such a scenario. In the world of reality, the very thought of it is absurd. And, even if the fetal tissue charges are true, who knew about this? Was this something that any of the doctors would have been aware of? I very seriously doubt it, especially when, as we shall see, Regeneron itself denies the charge.

Join over 250,000 others to get the top stories curated daily, plus special offers!

Join over 250,000 others to get the top stories curated daily, plus special offers!

It is therefore completely ridiculous to claim that Trump is being hypocritical in using Regeneron, as if he knew the alleged history of the drug.

But that leads us back to the big question: Did Regeneron use fetal tissue from a baby aborted in the 1970s?

Another headline on Business Insider stated, One of Trump's COVID-19 treatments was developed using tissue that originally came from an abortion. He's tried to ban this kind of research.

This is being widely reported as established fact. But is it true?

In an official statement for the pro-life Charlotte Lozier Institute, David Prentice, Ph.D. and Tara Sander Lee, Ph.D., wrote:

The Regeneron therapy given to the president was made in Velocimmune humanized mice, a novel platform that uses genetically modifiedmouse embryonic stem (ES)cells to generate antibodies describedhereandhere.Development of Regenerons antibody cocktail is detailed in the journalScience, describing how they identified their antibodies made from Velocimmune miceandblood from recovered patientspreviously infected with SARS-CoV-2.The final antibody pair used in theREGN-COV2 therapycocktail was then produced inChinese hamster ovary (CHO) cells.Results from Regenerons REGN-COV2 clinical trials to treat COVID-19 patients are reportedhere.

Mouseembryonic stem cells and genetic modifications to make such mice date back to 1981, have been extensively studied, and were instrumental in the discovery of induced pluripotent stem (iPS) cells, another fully ethical alternative to fetal material, as discussed in thisNaturereview.iPSCs are much easier to use thanhuman embryonic stem cells,more flexible in their uses, and are not ethically controversial. No one has ever advocated against using mouse embryonic stem cells for development of therapies only against destruction of human lives.

In a statement made to The Christian Post, Alexandra Bowie, a spokesperson for Regeneron, explained, We did not use human stem cells or human embryonic stem cells in the development of REGN-COV2. We did use the HEK293T cell line to test our antibodies ability to neutralize the SARS-CoV-2 virus (they were used to make pseudovirus that looks like the Spike protein).

HEK293s are considered immortalized cells and are a common and widespread tool in research labs. The cell line was originally derived by adenovirus transformation of human embryonic kidney cells in 1977.

After this, it was further transformed at Stanford in the 80s with SV40 T-antigen (hence the T). HEK293T wasnt used in any other way and fetal tissue was not used in this research.

Im not a medical doctor or a scientist, but it seems clear from these descriptions (and from what I could glean from Regenerons technical article published in the journal Science, also cited above) that there is hardly a direct connection between the drug and an aborted baby.

Still, there is so much misinformation going viral online that Dr. Tara Lee started a Twitter account just to rebut the misconceptions. (Lees Twitter bio identifies her as Researcher, Clinical Scientist, Science Policy Advisor. PhD. Senior Fellow & Director of Life Sciences @lozierinstitute. For LIFE in this world and the next.)

She summarized the evidence in simple and clear terms: NO human embryonic stem cells or human fetal tissue were used to produce the treatments President Trump received period.

So, Regeneron denies that it used embryonic cells and other scientists deny it. This completely undermines the charge that pro-life groups are being hypocritical for not condemning the use of the drug (and the presidents promotion of it).

That being said, some pro-life groups have, in fact, opined that, even if testing for the drug could be traced back to an abortion in the 1970s, Trump had nothing to do with any of this and is therefore not being hypocritical in promoting the drug.

Is there some hypocrisy in this response?

Thats a fair question, and its the type of question that ethicists debate. If you could save the lives of many people using a drug that was developed with the help of aborted fetal cells, is that justifiable?

My answer to those accusing the president with hypocrisy is threefold. First, as stated here, its unlikely in the extreme he had any idea of the alleged abortion connection. Second, scientists from Regeneron deny any connection to human fetal cells, and Trump would presumably take them at their word. Third, if Regeneron had been developed with the help of an aborted baby, there would then be a serious ethical debate as to its use.

Still, with all that being said, it is grasping at straws to question the pro-life commitment of these organizations (along with that of President Trump). Thats because we are comparing the willful killing of more than 60 million babies in the womb, often out of convenience, with the possible, distant connection of a life-saving drug to a baby aborted in the 1970s. Who would seriously make such a comparison?

When it comes to the question of the benefit of embryonic cells in the development of medical cures, Dr. Lee noted that, Fetal tissue from aborted babies is not required for medical advancements. After 100+ years of research, no therapies have been developed that needed aborted fetal tissue to begin with. Newer & better ethical alternatives are available & being used now to make humanized mice.

There is, therefore, no justification for using embryonic fetus cells in medical research, and the Regeneron drug does not contradict this at all.

Of course, as readers here know well, I have no problem identifying President Trumps many, evident shortcomings, some of which can be quite destructive. And I continue to shake my head over some of the things he says.

But to call him a hypocrite or to question his pro-life commitment because he used Regeneron is to reveal ones anti-Trump animus. It indicts the accuser far more than it indicts the accused.

Join over 250,000 others to get the top stories curated daily, plus special offers!

Join over 250,000 others to get the top stories curated daily, plus special offers!

Dr. Michael Brown(www.askdrbrown.org) is the host of the nationally syndicatedLine of Fireradio program. His latest book isEvangelicals at the Crossroads: Will We Pass the Trump Test?Connect with him onFacebook,Twitter, orYouTube.

Go here to see the original:
Regeneron, Trump, and the alleged hypocrisy of the pro-life movement - Christian Post

Life Sciences – a year to remember – Lexology

By Stem Cell Doctors

The Life Sciences sector has not been as newsworthy, pressured and flush with investors in living memory. The arrival of COVID-19 in 2020 has suddenly and emphatically focused attention on Life Sciences. The perception of the sector, and the reality of how it operates, has shifted. But in truth, Pharma was already changing.

Trends unrelated to the pandemic began with the shift away from searching for big-earning blockbuster drugs treating broad indications. Cost-effective opportunities in this type of market are dwindling, in the face of ever-increasing R&D and approval costs. Meanwhile, the shift to precision medicine has accelerated. Digital technology and biotechnology continue to make deeper inroads and stronger interconnections in how treatments are researched, developed and consumed. And those are just some of the developments.

Back in the distant, pre-COVID world of 2019, the Pharma industry was being dogged by the competing pricing concerns of payers and producers, with increasing pressure against companies seen to be benefiting from a monopoly on human health. Calls for tighter regulation on prices were particularly prevalent in the US, becoming a major theme of political debates.

A change in perception

Then along came COVID. Much as a global conflict usually sees major advances in weaponry, this global pandemic has seen a rapid boost in life science technology, collaboration and funding, as pharma companies, research organisations, SMEs and universities collectively search for a vaccine. The perception of Big Pharma has shifted correspondingly, from profiteers to potential saviours. It is probably true to say that never has so much been known about the sector by so many, in such a short space of time.

The growth of interest in Life Sciences has included investors; funding in 2020 has been incredibly strong. Biotech companies comprised 80% of all US IPOs in the first quarter and the US Nasdaq Biotechnology Index neared a five-year high in late April.

The US is the leader for investment by a big margin, but China has also seen some large investment rounds. Investors apparently see the sector as economy-proof and this is underpinned by a stronger public perception.

Tech advances

What of the technology? It has changed the R&D landscape, significantly reducing costs. Closer ties between tech and biotech are driving speedier, more targeted drug development, replacing the previous time-consuming trial and error required to prove theories. Interaction simulations can be run at the click of a button and clinical trials can progress more rapidly and cost-effectively through technology-aided efficiencies.

As R&D expense reduces and the remaining available blockbuster indications diminish, addressing smaller markets and niche illnesses has become more commercially viable alongside the long-standing medical needs. AI is invaluable in finding links in the rapidly accumulating global data resources. It is also creating more platform plays and modular business plans designed for biotech companies to bolt onto. And it is assisting clinicians by enabling faster, accurate reviews, such as analysing scans for breast cancer.

Enabling better prevention

Technology is also improving the quality of preventative medicine. Apps are helping doctors carry out remote diagnosis and secure more real-time, comprehensive feedback. Taking advantage of the Internet of Things, devices such as smart toilets can collect and analyse samples, and provide early warning of kidney or gastro-intestinal diseases. Spotting problems before they develop has physical, emotional and financial benefits for individuals, and the use of virtual coaches can support this by guiding patients through a healthier, preventative lifestyle.

More effective therapies

At the leading edge of life sciences, tech is helping new therapies to be better understood and utilised. Cell therapy is identifying and developing stem cells suitable for specialised uses, such as dopamine producers that could combat Parkinsons disease. Better gene editing tools are delivering improvements in gene therapy, while next-generation genome sequencing is allowing the development of precision medicines to previously unattainable levels.

The race for a vaccine

Crucially, and taking us back to where we started, vaccines can be constructed differently a point more pertinent than ever as science attempts to race towards an effective COVID-19 cure.

And its side effects

Is there a downside to all this? Yes. COVID has understandably monopolised attention and pushed back most other drug trials. Around half of non-COVID trials have been delayed this year, with critical developments put on hold and many biotech firms effectively in hibernation.

Whilst the true impact of these delays remains uncertain, there have nevertheless been a number of positives for the life sciences sector in 2020.

Positives for life sciences

Public and investor perception of pharma and life sciences has improved, with a resultant increase in funding and greater interest in careers in the sector. More specialised, precision medicine is giving fresh hope to those facing currently untreatable illnesses. Advances in tech-enabled diagnosis, drug development, dosing and monitoring have accelerated progress, with the spotlight on vaccines, genetic testing and monitoring leading to greater prominence on prevention.

Many of us are getting accustomed to the new normal acknowledging that post-COVID life will never be quite the same as it was before. The pandemic has resulted in a new normal emerging for life sciences too: greater collaboration, potentially faster trials and approval, and more integration of technology leading to more targeted and effective prevention and treatment.

Memories are often short, so how long life science advances will stay in the limelight is open to conjecture. But at this point in our state of the nation review, the life sciences sector is looking encouragingly healthy.

See more here:
Life Sciences - a year to remember - Lexology

PRP injections Treatment for Knee – WhaTech Technology and Markets News

By Platelet Rich Plasma Injections

Are you looking for a non-surgical treatment for your knee pain in Philadelphia? Rejuvenate Your Health in Allentown, PA, is here for you.

Rejuvenate Your Health is one of the best Platelet-Rich plasma (PRP) Therapy and Stem Cell therapy specialists in PA. PRP and Stem cell therapy are part of regenerative medicine therapies.

These regenerative medicines are the best non-surgical treatment for joint pain. If you are suffering from joint pain or knee pain, PRP injections can be the best choice for you.

"PRP therapy is like healing your body using itself." By that, they mean using your blood in the process to heal your injury. In PRP therapy, doctors take some of your blood and after processing the blood, they inject it into the place of injury to improve the healing process.

PRP therapy intensifies the body's natural healing process by delivering a higher concentration of platelets to the injured area.

PRP therapy is a simple process and can be performed in the office.

The treatment is performed under the local anesthesia and does not require general anesthesia or hospitalization. Patients can continue their daily work after half-hour from the treatment performed.

Many famous athletes like Philadelphia Phillies Aaron Nola, Tiger Woods and tennis star Rafael Nadal have benefited from PRP therapy.

Dr. Barry Ruht, specializes in body pain management, Stem-cell therapy and PRP injections in Philadelphia. Dr. Ruht and Rejuvenate Your Health, assures that their patients will recover their quickly and painlessly from their injuries.

Dr. Ruht, leads a team full of professionals is dedicated to a patient's recovery and a better life.

If you are unsure or have questions about the treatment and our services, you can contact us anytime. Patient care and satisfaction are considered the highest priority by Dr.

Ruht and his team at Rejuvenate Your Health.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read the rest here:
PRP injections Treatment for Knee - WhaTech Technology and Markets News

A pathway to nowhere? A critique of the National Academy of Sciences report on genome editing – BioNews

By Somatic Stem Cells

12 October 2020

Research Fellow in Biomedical Ethics, University of Melbourne/Murdoch Children's Research Institute

The transformative impact of CRISPR/Cas9 genome editing was recognised last week, with the Nobel Prize being awarded to its founders Jennifer Doudna and Emmanuelle Charpentier.

Since the prize winners first described this new approach to editing DNA, CRISPR has been used for hundreds of applications in biological research, agriculture, conservation biology and somatic medicine. However, its most controversial use has been in human reproduction, a practice called heritable genome editing (HGE). In 2018 Dr He Jiankui, an associate professor at the Southern University of Science and Technology in China announced he had used CRISPR to edit the CCR5 gene in embryos, resulting in twins who had already been born (see BioNews 997). The goal was to make the children resistant to infection from HIV.

Dr He Jiankui's announcement shocked the world and was condemned as a great violation of research ethics. In response, the US National Academy of Medicine, the US National Academy of Sciences, and the UK's Royal Society formed an 'International Commission on the Clinical Use of Human Germline Genome Editing' with the goal of 'defining a responsible pathway for clinical use of human HGE (HHGE), should a decision be made by any nation to permit its use' (see BioNews 1000). The outputs are a list of 11 recommendations that states should follow should they wish to implement HGE.

The strength of the report is the great detail it gives about the technical progress that has been made with genome editing technologies, their current limitations, and the hurdles such technologies should meet before we proceed to clinical applications. The report makes important general points like the need to engage with diverse communities likely to be affected by HGE.

However, in this article, I wish to discuss two reasons to be critical of the report. One concerns its framing and general relevance. The other is the way it categorises different possible future applications of HGE.

Framing and relevance

A convincing need for a clinical pathway for HGE is not provided in the Commission's report. The actions of Dr Jiankui, which were its catalyst, did not challenge our traditional clinical pathways. Dr Jiankui was a rogue actor, who took steps to hide what he was doing from others. His actions were incompatible with basic research ethics principles and existing guidelines for germline genome editing. If the goal is to prevent repeat actors like Dr Jiankui, we need to focus on compliance with existing standards rather than developing new ones.

Furthermore, if a specific clinical pathway for HGE is warranted, it's not clear why you would attempt to define one now. We are still far from having enough evidence to establish the safety of HGE. This will likely remain the case for some time, given restrictions on research in many places. Furthermore, HGE remains illegal in many parts of the world, including the USA, Europe, and the UK. No countries have announced intentions to relax laws and allow HGE, and China has recently passed legislation to restrict it. While the Commission's report is useful for suggesting some safety hurdles that must be cleared (for example recommendations five and six), the fact that we are so far from doing so raises questions about the need for further recommendations. Why not wait until we have safe technologies that some countries are considering implementing before devising detailed clinical pathways? As knowledge of the opportunities and risks posed by HGE increases, a pathway that is currently appropriate for HGE may well be obsolete in the future.

Categorising different applications

To further the above criticism, consider the six categories of HGE applications the Commission's report distinguishes:

A: Cases in which all of the prospective parents' children would inherit the disease-causing genotype for a serious monogenic disease (defined in this report as a monogenic disease that causes severe morbidity or premature death).

B: Cases in which some but not all of the prospective parents' children would inherit the pathogenic genotype for a serious monogenic disease.

C: Cases involving other monogenic conditions with less serious impact.

D: Cases involving polygenic diseases.

E: Cases involving other applications of HGE, including changes that would enhance or introduce new traits or attempt to eliminate certain diseases from the human population.

F: The special circumstance of monogenic conditions that cause infertility.

The Commission considers that only applications in Category A and some in Category B qualify for a clinical pathway. It's no doubt true that the most likely and logical initial application for HGE will be to prevent a serious monogenic disease, in cases where there are no other options. However, it's not clear whether other applications might become more compelling in the future, or indeed if there is a need to draw distinctions like this at all.

Consider how the report deals with applications to prevent infectious disease: a timely application considering we are currently experiencing a pandemic. Applications of HGE which gives individuals resistance to infectious disease are placed in Category E the same category as genes which enhance normal traits like intelligence. We are told a responsible clinical pathway cannot be defined for this application. But consider the following hypothetical case:

A new infectious disease Cebola has become endemic in some parts of the world, and no vaccine is available. Many die of Cebola in childhood. By altering one base-pair, it is possible to make children immune to Cebola. Base editing technologies are developed which can make these changes precisely, with no other changes made in the genome. It is possible to make individuals immune to Cebola by editing embryos used in IVF or editing men's spermatogonial stem cells.

Although such an application of HGE is unlikely, who knows what the world will be like by the time HGE is safe. The fact that this application is classed by the Commission's report in the same category as one which enhances intelligence is problematic, in my view. What is important is whether an application is safe and is expected to do good and prevent harm it doesn't matter ethically whether the harm would have been caused by an inherited disease or an infectious disease. What I think this shows is the need to assess HGE on an application by application basis, and not draw arbitrary distinctions far ahead of time.

Too many reports?

The Commission's report is the latest of dozens into genome editing and will be followed by another by the World Health Organisation soon. What often gets overlooked in these reports is the existing barriers to basic research into genome editing in germ cells, which is illegal or unfeasible in many parts of the world. If our goal is to use HGE to prevent the death and harm caused by genetic disease, we should be focusing on defining pathways that make responsible research easier around the world, rather than prematurely describing clinical pathways.

See the article here:
A pathway to nowhere? A critique of the National Academy of Sciences report on genome editing - BioNews

Should California invest $5.5 billion more into promising stem cell research? – The Mercury News

By Stell Cell Research
  1. Should California invest $5.5 billion more into promising stem cell research?  The Mercury News
  2. Prop. 14 Asks Voters To OK $5.5 Billion In Bonds For Additional Stem Cell Research  KPBS
  3. Editorial: California can't afford unneeded Prop 14 stem cell bond  Desert Sun
  4. What California's 2004 stem cell ballot proposition has meant for University of Southern California  Mirage News
  5. Danette Mitchell: Where I stand on the state propositions  Vacaville Reporter
  6. View Full Coverage on Google News

Original post:
Should California invest $5.5 billion more into promising stem cell research? - The Mercury News

Comprehensive Analysis on Stem Cell Therapy Market based on types and application – AlgosOnline

By Stell Cell Research

The ' Stem Cell Therapy market' study Added by Market Study Report, LLC, provides an in-depth analysis pertaining to potential drivers fueling this industry. The study also encompasses valuable insights about profitability prospects, market size, growth dynamics, and revenue estimation of the business vertical. The study further draws attention to the competitive backdrop of renowned market contenders including their product offerings and business strategies.

The Stem Cell Therapy market research report offers significant information related to the key growth drivers, challenges & limitations, and various opportunities that will define the business scenario in the upcoming years.

Request a sample Report of Stem Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2422751?utm_source=Algosonline.com&utm_medium=AN

According to the research analysis, the Stem Cell Therapy market is estimated to generate commendable returns and showcase a y-o-y growth rate of XX% over the period of 2020-20205.

The advent of COVID-19 pandemic has compelled various businesses to re-establish their respective profit trajectory for the forthcoming years. The study offers a comprehensive assessment of the impact of coronavirus outbreak on the growth of Stem Cell Therapy market.

The document also analyzes the several segmentations and their impact on the growth of this market.

Major highlights from the Stem Cell Therapy market report:

Ask for Discount on Stem Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2422751?utm_source=Algosonline.com&utm_medium=AN

Stem Cell Therapy Market segments covered in the research report:

Regional segmentation: North America, Europe, Asia-Pacific, South America, Middle East and Africa

Product types: Autologous and Allogeneic

Applications spectrum: Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases and Others

Competitive outlook: Osiris Therapeutics, Molmed, JCR Pharmaceutical, NuVasive, Anterogen, Chiesi Pharmaceuticals, Medi-post, Pharmicell and Takeda (TiGenix

The key questions answered in the report:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-stem-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Related Reports:

1. Global Transglutaminase Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Read More: https://www.marketstudyreport.com/reports/global-transglutaminase-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

2. Global Oral Spray Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Read More: https://www.marketstudyreport.com/reports/global-oral-spray-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Related Report : https://www.marketwatch.com/press-release/contactless-payment-market-share-current-and-future-industry-trends-2020-2026-2020-10-12?tesla=y

Contact Us: Corporate Sales, Market Study Report LLC Phone: 1-302-273-0910 Toll Free: 1-866-764-2150 Email: [emailprotected]

More here:
Comprehensive Analysis on Stem Cell Therapy Market based on types and application - AlgosOnline

How changing the stem cell response to inflammation may reverse periodontal disease – Bite magazine

By Stell Cell Research

Photo: Dmitrii Shironosov 123rf

US scientists have discovered that a specific type of molecule may stimulate stem cells to regenerate, reversing the inflammation caused by periodontal disease.

The current treatment for periodontal disease involves opening the infected gum flaps and adding bone grafts to strengthen the teeth.

But in research published inFrontiers in Immunology, scientists from the Forsyth Institute in Massachusetts have discovered that a specific type of molecule may stimulate stem cells to regenerate, reversing the inflammation caused by periodontal disease.

This finding could lead to the development of new therapeutics to treat a variety of systemic diseases that are characterised by inflammation in the body.

For the study, the team removed stem cells from previously extracted wisdom teeth and placed the stem cells onto petri dishes. They then created a simulated inflammatory periodontal disease environment in the petri dishes. Next, they added two specific types of synthetic molecules called Maresin-1 and Resolvin-E1, both specialised pro-resolving lipid mediators from omega-3 fatty acids.

The scientists found that Mar1 and RvE1 stimulated the stem cells to regenerate even under the inflammatory conditions.

Both Maresin-1 and Resolvin-1 reprogrammed the cellular phenotype of the human stem cells, showing that even in response to inflammation, it is possible to boost capacity of the stem cells so they can become regenerative, Dr Alpdogan Kantarci said.

This finding is important because it allows scientists to identify the specific protein pathways involved in inflammation. Those same protein pathways are consistent across many systemic diseases, including periodontal disease, diabetes, heart disease, dementia, and obesity.

Now that we understand how these molecules stimulate the differentiation of stem cells in different tissues and reverse inflammation at a critical point in time, the mechanism we identified could one day be used for building complex organs, Dr Kantarci said.

There is exciting potential for reprogramming stem cells to focus on building tissues.

Read the original:
How changing the stem cell response to inflammation may reverse periodontal disease - Bite magazine

Marcus Neuroscience Institute names Khalid A. Hanafy, M.D., Ph.D., Medical Director of Neurocritical Care and Research – Baptist Health South Florida

By Stell Cell Research

October 13th, 2020 Baptist Health South Florida

Boca Raton, FL October 13, 2020 Khalid A. Hanafy, M.D., Ph.D., has joined Marcus Neuroscience Institute at Boca Raton Regional Hospital, part of Baptist Health, as medical director of neurocritical care and director of research. He specializes in the care of subarachnoid hemorrhage patients and the study of neuroinflammation. He also serves as associate professor of neurology at Florida Atlantic University Charles E. Schmidt College of Medicine in Boca Raton. He is board certified in neurology and neurocritical care.

Dr. Hanafy joined Marcus Neuroscience Institute from Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Mass., where he served as the director of the neurological intensive care unit and was an assistant professor of neurology at Harvard Medical School.

We are pleased to welcome Dr. Hanafy to Marcus Neuroscience Institute, said Frank D. Vrionis, M.D., MPH, Ph.D., Institute director and chief of neurosurgery. His clinical skills, research acumen and leadership in the field of neurology will greatly benefit our team and our patients.

As the Institutes director of research, Dr. Hanafy is principal investigator of cutting-edge studies that seek to bring the most advanced, personalized treatments to subarachnoid hemorrhage patients and improve their survival rates and health outcomes. His groundbreaking work in neuroinflammation has been funded by the National Institutes of Health, American Heart Association, American Academy of Neurology, and Massachusetts Institute of Technology. Marcus Neuroscience Institute is at the forefront of stem cell therapeutics, and Dr. Hanafy and Dr. Vrionis have already initiated clinical trials using stem cells in critically ill COVID patients. Together, they will expand research and clinical trials using stem cells for the treatment of other neurological conditions, such as stroke and brain tumors.

Dr. Hanafy has authored more than 40 articles, book chapters and invited editorials in peer-reviewed scientific publications and serves on the editorial boards of scholarly journals in his field. He is a member of several professional societies, including the American Academy of Neurology, Society for Neuroscience Research, Society of Critical Care Medicine, and Neurocritical Care Society.

Dr. Hanafy earned his medical degree and doctorate degree in molecular biology at the University of Texas Medical Scientist Training Program at Houston, a dual degree program of the University of Texas McGovern Medical School and MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. He did his thesis graduate work under Dr. Ferid Murad, the 1998 Nobel laureate. He returned to these Houston facilities to complete a neurology residency following an internal medicine internship at the University of Texas Southwestern at Parkland Memorial Hospital in Dallas. He concluded his medical training with a two-year fellowship in neurological critical care at Columbia University Medical Center in New York City.

About the Marcus Neuroscience Institute The Marcus Neuroscience Institute at Boca Raton Regional Hospital is an innovative nexus for neurologic and neurosurgical care. The 57,000-square-foot facility houses a 20-bed Neuro Intensive Care and Step-Down Unit, four dedicated operating rooms including one equipped with intraoperative MRI and two with intraoperative CT capability and a biplane angiography suite, a crucial component in the diagnosis and care of neurological conditions. The Institute has a staff of five neurosurgeons and nine neurologists who represent some of the most respected clinicians in their fields and is affiliated with Florida Atlantic Universitys Charles E. Schmidt College of Medicine.

About Boca Raton Regional Hospital Boca Raton Regional Hospital is part of Baptist Health South Florida, the largest healthcare organization in the region, with 11 hospitals, nearly 23,000 employees, more than 4,000 physicians and more than 100 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to our faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the Worlds Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on Facebook, Instagram, Twitter and LinkedIn.

# # #

More here:
Marcus Neuroscience Institute names Khalid A. Hanafy, M.D., Ph.D., Medical Director of Neurocritical Care and Research - Baptist Health South Florida

Autologous Stem Cell and Non-Stem Cell Based Therapies Market To Witness Relatively Significant Growth During Forecast 2020 2027 – re:Jerusalem

By Stell Cell Research

The latestrelease from Database of Data Bridge Market Research has recently published the Global research Report TitledAutologous Stem Cell and Non-Stem Cell Based Therapies Market. The study provides an overview of current statistics and future predictions of the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry-validated market development data.

Europe autologous stem cell and non-stem cell based therapies market is registering a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. The rise in the market can be attributed growing awareness of the therapeutic potential of stem cells in effective disease management and increased public-private investment in the development of stem cell therapies.

Get Free Sample PDF (including COVID19 Impact Analysis) of Autologous Stem Cell and Non-Stem Cell Based Therapies MarketReport@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

(***Our Free Sample Copy of the report gives a brief introduction to the research report outlook, TOC, list of tables and figures, an outlook to key players of the market and comprising key regions.***)

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Autologous Stem Cell and Non-Stem Cell Based Therapies market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market in each region. Various methodological tools are used to analyze the growth of the worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Market Attributes

Details

Base Year for Estimation

2019

Historical Data

2016 2019

Forecast Period

2020 2027

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, And Trends

Major Regions as Follows

North America (USA, Canada and Mexico)

Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe)

Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, rest of countries etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

Prominent Key Players Covered in the report:

Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., General Electric Spiegelberg GmbH & Co. KG ., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Abbott., Endotronix, Inc. among others.Customization Available

A complete value chain of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market is presented in the research report. It is associated with the review of the downstream and upstream components of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

How Does This Market Insights Help?

Key Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast

Reasons to Purchase this Report

Market Dynamics:The Autologous Stem Cell and Non-Stem Cell Based Therapies report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

COVID-19 Impact Analysis:

The report seeks to track the evolution of the market growth pathways and publish a medical crisis in an exclusive section publishing an analysis of the impact of COVID-19 on the Autologous Stem Cell and Non-Stem Cell Based Therapies market. The new analysis of COVID-19 pandemic provides a clear assessment of the impact on the Autologous Stem Cell and Non-Stem Cell Based Therapies market and the expected volatility of the market during the forecast period. Various factors that can affect the general dynamics of the Autologous Stem Cell and Non-Stem Cell Based Therapies market during the forecast, including current trends, growth opportunities, limiting factors, etc., are discussed in detail in this market research.

Get Enquiry About This Comprehensive Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Why Is Data TriangulationImportantIn Qualitative Research?

This involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. Triangulation is one method used while reviewing, synthesizing and interpreting field data. Data triangulation has been advocated as a methodological technique not only to enhance the validity of the research findings but also to achieve completeness and confirmation of data using multiple methods

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

See original here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market To Witness Relatively Significant Growth During Forecast 2020 2027 - re:Jerusalem

The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% -…

By Stell Cell Research

October 08, 2020 05:14 ET | Source: ReportLinker

New York, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Regenerative Medicine Market by Product, Application, Geography - Global Forecast to 2025" - https://www.reportlinker.com/p04700208/?utm_source=GNW However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies.The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019.

The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications.In 2019, the oncology segment accounted for the highest growth rate.

This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine market The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World.The North America region is projected to grow at the highest CAGR during the forecast period in 2019.

The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

The primary interviews conducted for this report can be categorized as follows: By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35% By Designation: C-level - 30%, D-level - 20%, and Others - 50% By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, and Rest of the World 12%

Lits of companies Profiled in the Report: 3M (US) Allergan plc (Ireland) Amgen, Inc. (US) Aspect Biosystems (Canada) bluebird bio (US) Kite Pharma (US) Integra LifeSciences Holdings Corporation (US) MEDIPOST Co., Ltd. (South Korea) Medtronic plc (Ireland) Anterogen Co., Ltd. (South Korea) MiMedx Group (US) Misonix (US) Novartis AG (Switzerland) Organogenesis Inc. (US) Orthocell Limited (Australia) Corestem, Inc. (South Korea) Spark Therapeutics (US) APAC Biotech (India) Shenzhen Sibiono GeneTech Co., Ltd. (China) Smith & Nephew plc (UK) Stryker Corporation (US) Takeda Pharmaceutical Company Limited (Japan) Tego Science (South Korea) Vericel Corporation (US) Zimmer Biomet (US)

Research Coverage: This report provides a detailed picture of the global regenerative medicine market.It aims at estimating the size and future growth potential of the market across different segments, such as product, application, and region.

The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies.

This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and trends.

Read the full report: https://www.reportlinker.com/p04700208/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

The rest is here:
The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% -...

→←